Catherine Flaman - Entourage Health Senior Affairs
| ENTG Stock | 0.01 0.01 100.00% |
Executive
Catherine Flaman is Senior Affairs of Entourage Health Corp
| Address | 250 Elm Street, Aylmer, ON, Canada, N5H 2M8 |
| Phone | 844 933 3636 |
| Web | https://entouragehealthcorp.com |
Entourage Health Management Efficiency
The company has return on total asset (ROA) of (0.3679) % which means that it has lost $0.3679 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.711) %, meaning that it generated substantial loss on money invested by shareholders. Entourage Health's management efficiency ratios could be used to measure how well Entourage Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Entourage Health's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.33 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (1.40). At this time, Entourage Health's Total Current Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 9.64 in 2024, whereas Net Tangible Assets are likely to drop slightly above 18.3 M in 2024. Entourage Health Corp (ENTG) is traded on TSX Venture Exchange in Canada and employs 14 people. Entourage Health is listed under Pharmaceuticals category by Fama And French industry classification.Management Performance
| Return On Equity | -3.71 | ||||
| Return On Asset | -0.37 |
Entourage Health Corp Leadership Team
Elected by the shareholders, the Entourage Health's board of directors comprises two types of representatives: Entourage Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entourage. The board's role is to monitor Entourage Health's management team and ensure that shareholders' interests are well served. Entourage Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entourage Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Scorsis, Executive CEO | ||
| Pat Scanlon, Head Cultivation | ||
| Joseph Mele, Chief Officer | ||
| Alexandre Sibilev, VicePresident Compliance | ||
| Michael Kraft, Strategic board | ||
| Catherine Flaman, Senior Affairs | ||
| Deborah Sikkema, Chief Officer | ||
| Jeff Keyes, Senior Operations | ||
| Vaani Maharaj, Chief Officer | ||
| Marianella delaBarrera, Senior Affairs | ||
| Bruce DawsonScully, Advisor | ||
| James Afara, Chief Officer | ||
| Jonas Vanderzwan, Medical Board | ||
| Peter Blecher, Chief Officer |
Entourage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entourage Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Entourage Stock Analysis
When running Entourage Health's price analysis, check to measure Entourage Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entourage Health is operating at the current time. Most of Entourage Health's value examination focuses on studying past and present price action to predict the probability of Entourage Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entourage Health's price. Additionally, you may evaluate how the addition of Entourage Health to your portfolios can decrease your overall portfolio volatility.